| 1 |
33640455 | OTUB1 stabilizes mismatch repair protein MSH2 by blocking ubiquitination. | 2021 Jan-Jun |
1 |
| 2 |
33874956 | CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSĪ±/ATM-p73 axis in bladder cancer. | 2021 Apr 19 |
5 |
| 3 |
32922493 | A Preliminary Study of NER and MMR Pathways Involved in Chemotherapy Response in Bladder Transitional Cell Carcinoma: Impact on progression-free survival. | 2020 Winter |
1 |
| 4 |
30221354 | Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer. | 2019 Apr |
2 |
| 5 |
30414698 | A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. | 2019 Feb |
5 |
| 6 |
31666131 | Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer. | 2019 Oct 30 |
3 |
| 7 |
27995412 | HuCOP1 contributes to the regulation of DNA repair in keratinocytes. | 2017 Mar |
2 |
| 8 |
28536927 | Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours. | 2017 Aug |
3 |
| 9 |
23420099 | Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. | 2013 Feb |
1 |
| 10 |
23485110 | Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth. | 2013 Mar |
3 |
| 11 |
23724141 | MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. | 2013 |
1 |
| 12 |
23761438 | Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. | 2013 Aug |
1 |
| 13 |
22269178 | Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. | 2012 Sep |
1 |
| 14 |
22737591 | Molecular signaling mechanisms of apoptosis in hereditary non-polyposis colorectal cancer. | 2012 Jun 15 |
1 |
| 15 |
21285347 | MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. | 2011 Apr 8 |
1 |
| 16 |
21285353 | hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. | 2011 Mar 25 |
1 |
| 17 |
20145178 | MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. | 2010 Feb 15 |
1 |
| 18 |
23136600 | Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells. | 2010 Jan |
2 |
| 19 |
19484784 | Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. | 2009 Sep 1 |
1 |
| 20 |
19175039 | Analysis of hMLH1 and hMSH2 expression in cisplatin-treated ovarian cancer patients. | 2008 Dec |
2 |
| 21 |
17276589 | Hsp27, Hsp70 and mismatch repair proteins hMLH1 and hMSH2 expression in peripheral blood lymphocytes from healthy subjects and cancer patients. | 2007 Jul 8 |
1 |
| 22 |
16143448 | DNA damage and repair in peripheral blood lymphocytes from healthy individuals and cancer patients: a pilot study on the implications in the clinical response to chemotherapy. | 2006 Jul 28 |
2 |
| 23 |
16690105 | Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. | 2006 Nov |
2 |
| 24 |
16716446 | Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. | 2006 Jul |
1 |
| 25 |
14706347 | Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. | 2004 Feb 3 |
2 |
| 26 |
12736115 | Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. | 2003 May |
1 |
| 27 |
10048977 | Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. | 1999 Mar 1 |
2 |
| 28 |
10360646 | Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. | 1999 May |
1 |
| 29 |
10408416 | hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer. | 1999 Jul |
1 |
| 30 |
9647613 | Ongoing and unsaid on oxaliplatin: the hope. | 1998 Jun |
1 |
| 31 |
10397451 | Expression of hMSH2 correlates with in vitro chemosensitivity to CDDP cytotoxicity in oral and oropharyngeal carcinoma. | 1998 Oct 23 |
5 |
| 32 |
9157971 | In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. | 1997 May 15 |
1 |
| 33 |
9815561 | Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. | 1997 Oct |
1 |
| 34 |
21528244 | Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. | 1997 Sep |
2 |
| 35 |
8807890 | The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. | 1996 Jul |
5 |
| 36 |
8895738 | The role of DNA mismatch repair in platinum drug resistance. | 1996 Nov 1 |
2 |